Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:VSTM

Verastem Q1 2024 Earnings Report

Verastem logo
$5.96 +0.01 (+0.17%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 -0.06 (-1.01%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Verastem EPS Results

Actual EPS
-$1.26
Consensus EPS
-$1.16
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Verastem Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Verastem Announcement Details

Quarter
Q1 2024
Date
5/9/2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Verastem's Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Verastem's Q1 2024 Press ReleasePress Release
(8-K)
Verastem's Q1 2024 Quarterly reportQuarterly report
(10-Q)

Verastem Earnings Headlines

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260428101589/en/verastem-oncology-launches-hcp-and-patient-reimagine-campaign-to-increase-awareness-of-avmapki%c2%ae-fakzynja%c2%ae-co-pack-for-kras-mutated-recurrent-low-grade-serous-ovarian-cancer/
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages
April 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30747373
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260423119779/en/Verastem-Oncology-to-Report-First-Quarter-2026-Financial-Results-on-May-7-2026/
Buy Rating on Verastem: Favorable Risk‑Reward for VS‑7375 Driven by Superior Early Efficacy vs. Zoldonrasib and Improving Safety Outlook
April 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/buy-rating-on-verastem-favorable-risk‑reward-for-vs‑7375-driven-by-superior-early-efficacy-vs-zoldonrasib-and-improving-safety-outlook-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Vectoring In On Verastem
April 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891900-vectoring-in-on-verastem?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
See More Verastem Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email.

About Verastem

Verastem (NASDAQ:VSTM) Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes.

Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment.

View Verastem Profile
Earnings Tools